Telmisartan 80mg Non-responder Trial

Hypertension Clinical Trial

Official title:

An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg+ Amlodipine 5 mg Fixed-dose Combination vs. Telmisartan 80 mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg Monotherapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01222520
• Other study ID #: 1235.36
• Status: Completed
• Phase: Phase 3
• First received: October 15, 2010
• Last updated: June 17, 2014
• Start date: October 2010

Study information

• Verified date: January 2014
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Ministry of Health, Labor and Welfare
• Study type: Interventional

Clinical Trial Summary

If a patient cannot have his or her blood pressure controlled with telmisartan 80 mg, an antihypertensive drug from different class should be started concomitantly.

In the Japanese 3x3 factorial trial of telmisartan and hydrochlorothiazide in essential hypertension patients whose diastolic blood pressure (DBP) are equal or more than 95 mmHg, the DBP control rate (less than 90 mmHg) after 8 weeks treatment of the telmisartan 80 mg monotherapy group (66 patients) was 41.5%. There should be medical needs of the telmisartan 80 mg and amlodipine 5 mg fixed dose combination because some patients cannot have his or her blood pressure controlled with telmisartan 80 mg.

Thus, this clinical trial is being conducted to evaluate the antihypertensive effect and safety of a fixed-dose combination (FDC) drug of 2 antihypertensive agents with different pharmacological effects, telmisartan 80 mg and amlodipine 5 mg (T80/A5 mg), compared with telmisartan 80 mg (T80 mg) monotherapy in Japanese patients with essential hypertension who fail to respond adequately to treatment with the maximum dose of telmisartan 80 mg monotherapy. In this trial, a multi-centre, randomised, double-blind, double-dummy, active-controlled, parallel group comparison method is employed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 174
• Est. primary completion date: June 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years and older

Eligibility

Inclusion criteria:

• Essential hypertensive patients

• If already taking antihypertensive drugs, mean seated diastolic blood pressure (DBP) must be >=90 and >=114 mmHg

• If not taking any antihypertensive drugs, mean seated DBP must be >=95 and >=114 mmHg

• Able to stop all current antihypertensive drugs without risk to the patient based on the investigators opinion.

Exclusion criteria:

• Patients taking 3 or more antihypertensive drugs at signing the informed consent form

• Patients with known or suspected secondary hypertension

• Patients with clinically relevant cardiac arrhythmia

• Congestive heart failure with New York Heart Association (NYHA) functional class III-IV

• Patients with recent cardiovascular events

• Patients with a history of stroke or transient ischaemic attack within last 6 months before signing the informed consent form

• Patients with a history of sudden deterioration of renal function with angiotensin II receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors; or patients with post-renal transplant or post-nephrectomy

• Patients who have previously experienced characteristic symptoms of angioedema (such as facial, tongue, pharyngeal, or laryngeal swelling with dyspnea) during treatment with ARBs or ACE inhibitors

• Patients with known hypersensitivity to any component of the investigational product, or a known hypersensitivity to dihydropyridine-derived drugs

• Patients with hepatic and/or renal dysfunction

• Pre-menopausal women who are nursing or pregnant

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hypertension

Intervention

Drug:
• Telmisartan and amlodipine
Telmisartan 80 mg and amlodipine 5 mg once a daily
• Telmisartan
80 mg once a daily

Locations

Country	Name	City	State
Japan	1235.36.01 Boehringer Ingelheim Investigational Site	Chuo-ku,Tokyo
Japan	1235.36.04 Boehringer Ingelheim Investigational Site	Hiroshima, Hiroshima
Japan	1235.36.02 Boehringer Ingelheim Investigational Site	Shinjuku-ku, Tokyo
Japan	1235.36.03 Boehringer Ingelheim Investigational Site	Suita, Osaka

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reduction From the Reference Baseline in Mean Seated Diastolic Blood Pressure (DBP) at Trough	Reference baseline: Status of patients after the 8-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing	Baseline, 8 weeks	No
Secondary	Reduction From the Reference Baseline in Mean Seated Systolic Blood Pressure (SBP) at Trough	Reference baseline: Status of patients after the 8-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing	Baseline, 8 weeks	No
Secondary	Seated DBP Control Rate at Trough	DBP control rate: The rate of patients with controlled seated DBP at trough of less than 90 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing	8 weeks	No
Secondary	Seated SBP Control Rate at Trough	SBP control rate: The rate of patients with controlled seated SBP at trough of less than 140 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing	8 weeks	No
Secondary	Seated DBP Response Rate at Trough	DBP response rate: The rate of patients who achieved an adequate response in seated DBP at trough (<90 mmHg and/or reduction from reference baseline =10 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing	8 weeks	No
Secondary	Seated SBP Response Rate at Trough	SBP response rate: The rate of patients who achieved an adequate response in seated SBP at trough (<140 mmHg and/or reduction from reference baseline =20 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing	8 weeks	No
Secondary	Seated Blood Pressure (BP) Normalisation at Trough	Seated blood pressure (BP) normalisation: The numbers of patients whose blood pressure was within normalisation criterion in terms of seated blood pressure after the 8-week double-blind period At trough: 24-hour post-dosing	8 weeks	No

External Links

•   Link
•   Link